KalVista Pharmaceuticals (KALV) Accumulated Expenses (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Accumulated Expenses of $19.0 million in Q3 2025, down 30.53% quarter-over-quarter from $27.3 million in Q2 2025, and up 83.21% year-over-year from $10.4 million in Q3 2024.
KalVista Pharmaceuticals' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $19.0 million for Q3 2025.
- In Q3 2025, Accumulated Expenses rose 83.21% year-over-year to $19.0 million; the TTM figure through Jul 2025 stood at $19.0 million (up 83.21% YoY), while the FY2025 annual figure was $27.3 million, up 308.36% from the prior year.
- Accumulated Expenses came in at $19.0 million for Q3 2025 at KalVista Pharmaceuticals, down from $27.3 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $27.3 million in Q2 2025 to a low of $2.4 million in Q4 2021.
- A 5-year average of $7.5 million and a median of $5.9 million in 2021 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses tumbled 57.09% in 2023 and surged 314.03% in 2024, its largest moves.
- KalVista Pharmaceuticals' Accumulated Expenses stood at $2.4 million in 2021, then gained by 28.74% to $3.1 million in 2022, then increased by 24.65% to $3.9 million in 2023, then surged by 116.35% to $8.3 million in 2024, then jumped by 127.58% to $19.0 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $19.0 million, $27.3 million, and $8.3 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 18.97 Mn |
| Apr 30, 2025 | 27.31 Mn |
| Dec 31, 2024 | 8.34 Mn |
| Oct 31, 2024 | 6.98 Mn |
| Jul 31, 2024 | 10.36 Mn |
| Apr 30, 2024 | 6.69 Mn |
| Jan 31, 2024 | 5.47 Mn |
| Oct 31, 2023 | 3.85 Mn |
| Jul 31, 2023 | 2.50 Mn |
| Apr 30, 2023 | 4.21 Mn |
| Jan 31, 2023 | 4.12 Mn |
| Oct 31, 2022 | 3.09 Mn |
| Jul 31, 2022 | 5.83 Mn |
| Apr 30, 2022 | 6.96 Mn |
| Jan 31, 2022 | 6.45 Mn |
| Oct 31, 2021 | 2.40 Mn |
| Jul 31, 2021 | 5.88 Mn |
| Apr 30, 2021 | 6.93 Mn |
| Jan 31, 2021 | 5.29 Mn |
| Oct 31, 2020 | 2.95 Mn |
| Jul 31, 2020 | 6.17 Mn |
| Apr 30, 2020 | 5.46 Mn |
| Jan 31, 2020 | 4.88 Mn |
| Oct 31, 2019 | 5.03 Mn |
| Jul 31, 2019 | 4.26 Mn |
| Apr 30, 2019 | 1.95 Mn |
| Jan 31, 2019 | 1.17 Mn |
| Oct 31, 2018 | 2.99 Mn |
| Jul 31, 2018 | 3.14 Mn |
| Apr 30, 2018 | 1.39 Mn |
| Jan 31, 2018 | 1.05 Mn |
| Oct 31, 2017 | 2.25 Mn |
| Jul 31, 2017 | 1.69 Mn |
| Apr 30, 2017 | 1.87 Mn |
| Jan 31, 2017 | 2.45 Mn |
| Mar 31, 2016 | 1.08 Mn |
| Dec 31, 2015 | 1.33 Mn |
| Sep 30, 2015 | 1.27 Mn |
| Jun 30, 2015 | 586,000.00 |
| Mar 31, 2015 | 1.83 Mn |
| Dec 31, 2014 | 1.61 Mn |